Stock Events

Stock Events

uniQure N.V. 

$43.68
104
-$0.38-0.86% Tuesday 20:00
-$0.05-0.11%Tuesday 23:41After hours

Statistics

Day High
43.82
Day Low
43.7
52W High
71.5
52W Low
8.73
Volume
37,474
Avg. Volume
-
Mkt Cap
3.03B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.49
-1.21
-0.93
-0.65
Expected EPS
-0.907958
Actual EPS
N/A

Financials

-1,236%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
16.1MRevenue
-198.97MNet Income

Analyst Ratings

53.90Average Price Target
The highest estimate is 80.00.
From 10 ratings within the last 6 months. This is not an investment recommendation.
Buy
80%
Hold
20%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow QURE. It's not an investment recommendation.
NVIDIA
22
NVDA
Tesla
18
TSLA
Alphabet
18
GOOGL
Microsoft
17
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.43B
BioMarin Pharmaceutical Inc. develops and commercializes innovative therapies for rare genetic diseases, overlapping with uniQure's target market.
Pfizer
PFE
Mkt Cap137.76B
Pfizer Inc., through its acquisition of Bamboo Therapeutics and Spark Therapeutics, has expanded into gene therapy, making it a competitor in the same field as uniQure.
Regenxbio
RGNX
Mkt Cap721.18M
REGENXBIO Inc. is a biotechnology company that develops AAV-based gene therapies for genetic and other diseases, competing in the same space as uniQure.
Sarepta Therapeutics
SRPT
Mkt Cap2B
Sarepta Therapeutics, Inc. specializes in the discovery and development of RNA-based and gene therapy treatments for rare diseases, making it a competitor in the gene therapy market.
Intellia Therapeutics
NTLA
Mkt Cap1.99B
Intellia Therapeutics, Inc. is involved in CRISPR/Cas9 gene editing, a next-generation technology that could compete with uniQure's gene therapy approaches.
CRISPR Therapeutics
CRSP
Mkt Cap5.25B
CRISPR Therapeutics AG focuses on the development of gene-based medicines using the CRISPR/Cas9 system, competing in the broader gene therapy and editing market alongside uniQure.

About

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Show more...
CEO
Mr. Matthew Craig Kapusta CPA
Employees
221
Country
Netherlands
ISIN
NL0010696654

Listings

MX
MX
QUREN.MX
STU
DE
UQ1.STU
XNAS
US
QURE
LSE
GB
0EE0.LSE

0 Comments

Share your thoughts

FAQ

What is uniQure N.V. stock price today?▼
The current price of QURE is $43.68 USD — it has decreased by -0.86% in the past 24 hours. Watch uniQure N.V. stock price performance more closely on the chart.
What is uniQure N.V. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange uniQure N.V. stocks are traded under the ticker QURE.
Is uniQure N.V. stock price growing?▼
QURE stock has risen by +9.01% compared to the previous week, the month change is a +4.47% rise, over the last year uniQure N.V. has showed a +212% increase.
What is uniQure N.V. market cap?▼
Today uniQure N.V. has the market capitalization of 3.03B
When is the next uniQure N.V. earnings date?▼
uniQure N.V. is going to release the next earnings report on November 10, 2026.
What were uniQure N.V. earnings last quarter?▼
QURE earnings for the last quarter are -1.22 USD per share, whereas the estimation was -0.82 USD resulting in a -48.37% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is uniQure N.V. revenue for the last year?▼
uniQure N.V. revenue for the last year amounts to 16.1M USD.
What is uniQure N.V. net income for the last year?▼
QURE net income for the last year is -198.97M USD.
How many employees does uniQure N.V. have?▼
As of August 05, 2026, the company has 221 employees.
In which sector is uniQure N.V. located?▼
uniQure N.V. operates in the Health & Wellness sector.
When did uniQure N.V. complete a stock split?▼
uniQure N.V. has not had any recent stock splits.
Where is uniQure N.V. headquartered?▼
uniQure N.V. is headquartered in Amsterdam, Netherlands.